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Medical Abortion Provision
by Pharmacies and Drug Sellers
in Low- and Middle-Income Countries:
A Systematic Review
Katharine Footman, Katherine Keenan, Kate Reiss, Barbara Reichwein,
Pritha Biswas, and Kathryn Church
Weundertook a systematic review to assess 1) the level and quality of pharmacy
and drug shop provision of medical abortion (MA) in low- andmiddle-income
countries (LMICs) and 2) interventions to improve quality of provision. We
used standardized terms to search six databases for peer-reviewed and grey lit-
erature. We double-extracted data using a standardized template, and double-
graded studies for methodological quality. We identified 22 studies from 16
countries reporting on level and quality of MA provision through pharmacies
and drug sellers, and three intervention studies. Despite widespread awareness
and provision of MA drugs, even in legally restricted contexts, most studies
found that pharmacy workers and drug sellers had poor knowledge of effective
regimens. Evidence on interventions to improve pharmacy and drug shop pro-
vision of MAwas limited and generally low quality, but indicated that training
could be effective in improving knowledge. Programmatic attention should fo-
cus on the development and rigorous evaluation of innovative interventions to
improvewomen’s access to information aboutMA self-management in low-and
middle-income countries.
An estimated 7 million women in the developing world were treated for complica-tions from unsafe abortion in 2012 (Singh and Maddow-Zimet 2015), and deathsdue to complications of unsafe abortion have been estimated to account for between
8 and 18 percent of all maternal deaths (Graham et al. 2017; Say et al. 2014). On the other
hand, there have been global declines in case-fatality fromunsafe abortions since 1990, which
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have in part been attributed to a shift from higher- to lower-risk methods of unsafe abor-
tion, including self-administeredmedical abortion (MA) pills (Fernandez, Coeytaux, Gomez
Ponce de León, and Harrison 2009; World Health Organization 2011). Medical abortion is a
non-surgical method of abortion administered through the use of the pharmaceutical drugs
mifepristone and misoprostol, or misoprostol alone. Misoprostol is a WHO-approved drug
for MA that is widely available in pharmacies in low- and middle-income countries (LMICs)
as it has other indications including treatment of gastric ulcers and postpartum hemorrhage.
The availability ofmisoprostol in pharmacies and drug shops has increasedwomen’s access to
a safer alternative to othermethods of self-induced abortion (Hyman et al. 2013), and increas-
ing availability of misoprostol has also been linked to declining abortion-related morbidity
in some countries (Faúndes, Santos, Carvalho, and Gras 1996). Misoprostol is more effec-
tive for inducing a safe abortion when used in combination with mifepristone, although a
misoprostol-only regimen is recommended where mifepristone is unavailable (World Health
Organization 2012). The combined regimen of mifepristone and misoprostol is also increas-
ingly available in pharmacies in some countries, though mifepristone is much less widely
available than misoprostol since its main use is for medical abortion and its registration is
often therefore prevented by political sensitivities related to abortion (Culwell and Hurwitz
2013).
Pharmacies and drug shops are often the first, preferred source of health care in
LMICs in light of their convenience, privacy, anonymity, and low cost (Ahmed and Hossain
2007; Chalker et al. 2000; Goel, Ross-Degnan, Berman, and Soumerai 1996). Although
a prescription is often legally required for selling misoprostol or mifepristone, sale of
drugs without prescription is common in many LMICs (Goodman et al. 2007). Although
studies show that MA is safe, effective, and easily self-administered in low-resource set-
tings (Harper et al. 2007), effective use of MA drugs requires that women receive ade-
quate information and counseling and high-quality products (World Health Organization
2012).
A review of pharmacy provision ofMA, published in 2012 (Sneeringer, Billings, Ganatra,
and Baird 2012), found that pharmacy workers rarely offer adequate information to women
buying MA. Since 2012, however, research on pharmacy and drug shop provision of MA
has expanded rapidly. Moreover, the 2012 study did not take a systematic approach to the
literature search, nor find evidence from intervention studies on how provision quality
could be improved. The present study is a systematic review that builds on this previous
work to meet two objectives: 1) to describe the level and quality of pharmacy and drug
shop provision of MA in LMICs; and 2) to assess the effectiveness and cost-effectiveness
of interventions aiming to improve the level and/or quality of MA provision by pharmacy
workers and drug sellers. We review the evidence both on the provision of misoprostol-only
and the mifepristone-misoprostol combined regimen of medical abortion and on provi-
sion of other, ineffective drugs that may be sold to women seeking abortion. In addition,
the term pharmacy can refer to a range of businesses of various sizes and legal status,
and in this article we refer to pharmacies and drug shops as any outlet whose business is
selling medicines, regardless of the training and qualifications of their staff or their legal
status.
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MATERIALS ANDMETHODS
Six online databases (MEDLINE, Web of Science, POPLINE, Embase, Global Health, and
WHO Reproductive Health Library) were searched using standardized search terms (Table
1).1 For objective 1, search terms related to abortion and to pharmacies, drug sellers, or self-
medication were used (row 1 and 2, Table 1). For objective 2, additional search terms related
to interventions were added (rows 1–3). Further studies (including peer-reviewed papers and
grey literature) were identified using snowball techniques applied to reference lists of identi-
fied studies.
Studies were screened for inclusion by title and abstract, were further screened by full
text, and were included if they met the following criteria: outcomes met the review objec-
tives; study design used quantitative primary data collection methods; published between 1
January 1990 and 1 April 2017; in English, Spanish, or French; LMIC setting (defined using
the latest World Bank data http://data.worldbank.org/about/country-and-lending-groups);
published peer-reviewed articles or grey literature (published reports including a formal re-
search element). Grey literature was considered for inclusion if a study was reported in suf-
ficient detail to extract data and assess quality, and if there was a formal evaluation element
for intervention studies. Conference abstracts were included if we could access full-length
papers with sufficient detail for quality assessment. Studies reporting provision of any type of
medication intended to end a pregnancy were included, irrespective of whether the products
provided were safe or effective abortifacients. Both quasi- and fully experimental interven-
tion study designs were included. Abstracts and studies in French or Spanish were screened
by colleagues with working proficiency in that language, and one Spanish-language study was
selected for inclusion following assessment by a co-author fluent in the language.
Among the identified studies, data were double-extracted using a standardized template
and results were summarized narratively. For objective 1, we extracted the following data:
study setting, study design (including sampling and limitations), outlet type, population out-
comes measured, and comparisons made. We considered various outcomes indicating level
and quality of provision, including types of abortifacients offered/sold, knowledge of and
counseling on effective regimen and complications, and prescription requirements. For ob-
jective 1,methodological quality was assessed by two reviewers using a standardized checklist
of ten items on prevalence design and reporting (Munn,Moola, Riitano, and Lisy 2014). This
checklist included recruitment, representativeness, sample size, measurement, analysis, and
whether confounders and subgroups were considered (see full list and scores in Table 2).
Differences in scoring were reconciled through discussion, and on the few occasions when
an agreement could not be reached, a third opinion was sought. An overall index score was
calculated for each study (0 points for each criteria not reported or met, 1 point if partially
met, and 2 points if fully met). For studies with multiple outcomes, quality assessment of the
various outcome measurements was averaged to produce an overall score. The quality of the
study was considered to be low if the total score was less than 50 percent of the potential
score, medium if 50–75 percent, and high if greater than 75 percent.
1 Tables are available at the supporting information tab at wileyonlinelibrary.com/journal/sfp.
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For objective 2, the following data were extracted: intervention description, study setting,
population, study design (including any randomization procedure, sampling, and compari-
son group), outcome, analysis method, and results. The quality of the intervention studies for
objective 2 was also assessed by two reviewers using a checklist of 11 items adapted from the
Critical Appraisal Skills Programme (CASP) (http://www.casp-uk.net/casp-tools-checklists),
amended to allow applicability to both randomized and quasi-experimental studies (see
Table 3). An overall score was calculated by giving 0 points for notmeeting criteria/unknown,
1 point for partially meeting, and 2 points for meeting criteria. Study quality was graded
with the following scores: 0–11, low quality; 12–17, medium quality; and 18–22, high quality.
Scores were adjusted proportionally in the case of a lower denominator. Given the hetero-
geneity of outcomes and study designs, it was determined that meta-analysis would not be
appropriate.
RESULTS
Objective 1: Level of Provision and Provision Practices
Characteristics of Studies and Study Populations
Figure 1 describes the search process for objective 1. Table 4 describes the main character-
istics of the 22 studies selected for inclusion for objective 1. Most (20) were peer-reviewed
journal articles, one was a conference paper (Reiss et al. 2015b), and the other was a grey
literature research report (Zamberlin 2007). The earliest study was published in 1991 (con-
ducted in 1985), but most were published since 2010; 13 of those had not been included in
an earlier literature review on this topic (Sneeringer, Billings, Ganatra, and Baird 2012). The
studies were conducted in various locations in Latin America (Billings et al. 2009; Bonnema
and Dalebout 1992; de Oddone et al. 1991; Lara, Garcia, Wilson, and Paz 2011; Miller et al.
2005; Zamberlin 2007), sub-Saharan Africa (Adinma and Adinma 2013; Akiode et al. 2010;
Fetters et al. 2015; Hendrickson et al. 2015; Reiss et al. 2017) South Asia (Huda et al. 2014;
Mishra et al. 2016; Powell-Jackson, Acharya, Filippi, and Ronsmans 2015; Reiss et al. 2015b;
Tamang, Puri, Lama, and Shrestha 2015; Tamang and Tamang 2005), and South East Asia
(Ngo, Park, and Nguyen 2012). In two of the locations, legal restrictions on abortion did not
make exceptions to save the mother’s life at the time of study (Senegal and Dominican Re-
public); in the majority abortion was allowed only to save the mother’s life or to preserve her
health (Nigeria, Mexico, Peru, Paraguay, Bangladesh, Kenya, and Argentina); and in the re-
maining locations abortion was available on socioeconomic grounds or on request (Zambia,
India, Vietnam, and Nepal).
The combined regimen of misoprostol and mifepristone was approved for use for MA
in six of the locations at the time of study (Bangladesh, India, Zambia, Vietnam, Kenya, and
Nepal) (Fetters et al. 2015;Ganatra,Manning, andPallipamulla 2005;Hendrickson et al. 2015;
Mishra et al. 2016; Ngo, Park, and Nguyen 2012; Powell-Jackson, Acharya, Filippi, and Ron-
smans 2015; Reiss et al. 2015b; Reiss et al. 2016; Tamang, Puri, Lama, and Shrestha 2015).
In all other locations misoprostol was registered for use to treat other illnesses such as gas-
tric ulcers, but not for MA. Most studies were conducted in urban settings and involved
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FIGURE 1 Summary of search results for objective 1
NOTE: MA=medical abortion. PAC= post-abortion care.
interviewswith pharmacyworkers (10 studies: Adinma andAdinma 2013; Akiode et al. 2010;
de Oddone et al. 1991; Fetters et al. 2015; Ganatra, Manning, and Pallipamulla 2005; Mishra
et al. 2016; Reiss et al. 2015b,; Reiss et al. 2016; Reiss et al. 2017; Tamang and Tamang 2005),
mystery client surveys (where trained researchers pretend to be clients and record their expe-
riences) (6 studies: Billings et al. 2009; Hendrickson et al. 2015; Huda et al. 2014; Lara, Garcia,
Wilson, and Paz 2011; Miller et al. 2005; Zamberlin 2007), or a combination of the two
(6 studies: Bonnema and Dalebout 1992; Lara, Abuabara, Grossman, and Díaz-Olavarrieta
2006; Ngo, Park, and Nguyen 2012; Powell-Jackson, Acharya, Filippi, and Ronsmans 2015;
Reiss, Aung, Aung, and Ngo 2014; Reiss et al. 2016). Indicators used to report MA provi-
sion varied considerably between studies, including for example: “stocking” or “selling” MA
drugs in pharmacy worker surveys, and “offering,” “recommending,” mentioning,” and “dis-
cussing”MAdrugs inmystery client surveys. Distinctions were alsomade between prompted
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and spontaneousmentions of abortifacients in twomystery client surveys (Billings et al. 2009;
Lara, Garcia, Wilson, and Paz 2011).
Studies were conducted in a range of outlet types: some sampling frames included all out-
lets that sold drugs (whether registered or not) (Ganatra, Manning, and Pallipamulla 2005;
Huda et al. 2014; Powell-Jackson, Acharya, Filippi, and Ronsmans 2015; Reiss, Aung, Aung,
andNgo 2014); some did not specify registration status (Bonnema andDalebout 1992;Miller
et al. 2005; Mishra et al. 2016; Zamberlin 2007); and the rest used lists of registered pharma-
cies. Respondents were not always specified, but included salespersons, owners, or managers.
Of the 13 studies that reported respondents’ education or qualifications, a substantial pro-
portion had higher education and/or specialist training. In 10 of the studies, the majority of
pharmacy workers were qualified as pharmacists, had been trained to dispense medicines, or
had professional training, a bachelor’s degree, or a diploma in pharmacy. In 4 of the studies,
the person invited for interview was the most senior, or the owner of the pharmacy, rather
than the person most often working behind the counter.
Studies were of variable methodological quality: 7 were graded as high, 11 medium,
and 4 low quality (see Table 2). Low-quality studies typically had unrepresentative sam-
ples, inadequate recruitmentmethods, underpowered sample sizes, and inadequate statistical
analysis.
Level of Abortifacient Provision
Table 5 shows data extracted on level and practice of abortifacient provision by pharmacy
workers and drug sellers. The proportion of outlets offering abortifacients varied widely by
setting, by legal status of abortion, and over time. High levels of provision were seen even in
legally restrictive settings such as Latin America (Bonnema and Dalebout 1992; Huda et al.
2014; Reiss et al. 2015b). In most studies where both surveys and mystery clients were used,
higher provision rates were reported by the latter (Powell-Jackson, Acharya, Filippi, and Ron-
smans 2015; Reiss, Aung, Aung, and Ngo 2014, 2016). Two studies found that provision was
alsomore commonwhenmystery clients asked directly aboutmisoprostol or a specific brand
of drug, rather than asking generally about a medication to induce abortion (Billings et al.
2009; Lara, Garcia,Wilson, and Paz 2011).Misoprostol-only was themore commonly offered
MA regimen, except in one recent Indian study (Powell-Jackson, Acharya, Filippi, and Ron-
smans 2015). In sub-Saharan Africa, self-reported provision of misoprostol for abortion was
low: less than 1 percent of pharmacies in a study in Senegal in 2013 (Reiss et al. 2017) and
3 percent of pharmacies in Nigeria in 2006 (Akiode et al. 2010). One mystery client study
in Kenya in 2013, however, reported higher provision levels (26 percent) (Reiss et al. 2016).
In a repeated mystery client survey in Zambia , a significant increase in misoprostol provi-
sion was recorded, from 51 percent in 2009 to 72 percent in 2011 (Hendrickson et al. 2015).
Misoprostol provision to mystery clients was common in legally restrictive settings such as
Latin America (which studies were of mixed quality), ranging from 78–90 percent in Mexico
(Billings et al. 2009; Lara, Garcia, Wilson, and Paz 2011) to 64 percent in the Dominican Re-
public (Miller et al. 2005) and 55 percent in Argentina (Zamberlin 2007). In Asia, two surveys
in Bangladesh (Huda et al. 2014; Reiss et al. 2015b) and one Indian study (Powell-Jackson,
Acharya, Filippi, and Ronsmans 2015) also found that misoprostol provision in pharmacies
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and drug shops was relatively common. Provision of the mifepristone-misoprostol combina-
tion to mystery clients was most commonly found in studies in South Asia where abortion
was less legally restricted, particularly in India where 34 percent of chemists in Bihar and
Jharkland reported selling the combination regimen in surveys in 2005 (Ganatra, Manning,
and Pallipamulla 2005), and 67 percent reported selling the combination regimen in a 2015
study (Powell-Jackson, Acharya, Filippi, and Ronsmans 2015).
Provision of other types of abortifacients was also reported and observed. A 2014
study in an unnamed South East Asian city, where safe, legal abortion is highly restricted,
found provision of misoprostol was uncommon, and almost half of mystery clients were
offered an ineffective drug: either oral or emergency contraceptives, traditional medicines,
or Penorit (a hormone preparation for secondary amenorrhea designed to restore men-
struation) (Reiss, Aung, Aung, and Ngo 2014). In India, Nepal, and Bangladesh pro-
vision of ayurvedic and herbal abortion preparations was also commonly observed in
pharmacy and drug seller surveys (Tamang and Tamang 2005; Huda et al. 2014; Powell-
Jackson, Acharya, Filippi, and Ronsmans 2015). Sales of high-dose contraceptives or hor-
monal injections were commonly reported by pharmacy workers and mystery clients in sur-
veys in Latin America during the early 1990s (de Oddone et al. 1991; Bonnema and Dalebout
1992).
Provision Practices and Knowledge
Pharmacy worker/drug seller knowledge of or counseling on an effectivemisoprostol-only or
mifepristone-misoprostol regimen was poor, ranging from 3 to 17 percent in Latin America
(Billings et al. 2009; Lara, Abuabara, Grossman, and Díaz-Olavarrieta 2006; Lara, Garcia,
Wilson, and Paz 2011), from 9 to 41 percent in Asia (Ganatra, Manning, and Pallipamulla
2005; Huda et al. 2014; Mishra et al. 2016; Powell-Jackson, Acharya, Filippi, and Ronsmans
2015; Reiss et al. 2015b, Reiss, Aung, Aung, and Ngo 2014), and from 0 to 21 percent in
Africa (Hendrickson et al. 2015; Reiss et al. 2016; Reiss et al. 2017). A recent high-quality
study in India comparing data from a mystery client study and a drug seller survey found
that knowledge did not translate into accurate advice to clients: while 51 percent of pharmacy
workers had correct knowledge of the dosage and timing of the combined regimen for MA,
only 35 percent provided correct information to clients (Powell-Jackson, Acharya, Filippi,
and Ronsmans 2015).
In the 8 mystery client studies reporting whether a prescription was requested, less than
half of clients were asked for a prescription, ranging from none in a restrictive South East
Asian city (Reiss, Aung, Aung, and Ngo 2014) to 40 percent in Zambia (Hendrickson et al.
2015) and Argentina (Zamberlin 2007). There was also wide variation in advice given re-
garding potential complications in the 10 mystery client studies reporting on this indica-
tor, ranging from 0 percent in Peru (Bonnema and Dalebout 1992) to 78–100 percent in
Zambia (Hendrickson et al. 2015). Referral to other providers in the case of complications
was low in studies from Peru and Argentina (Bonnema and Dalebout 1992; Zamberlin 2007)
but relatively high (above 50 percent) in several studies from India (Ganatra, Manning, and
Pallipamulla 2005; Mishra et al. 2016), Mexico (Billings et al. 2009), Vietnam (Ngo, Park, and
Nguyen 2012), and Bangladesh (Reiss et al. 2015b).
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FIGURE 2 Summary of search results for objective 2: MA through pharmacy intervention
studies
Objective 2: Interventions to Improve the Level or Quality of MA
Pharmacy Provision
We found three studies evaluating interventions to improve the quality of pharmacy and drug
shop provision of MA (see Figure 2 and Table 6).
Characteristics of Studies
The three studies were conducted in Zambia, Bangladesh, and Nepal. Two were reported in
peer-reviewed journals (Fetters et al. 2015; Tamang, Puri, Lama, and Shrestha 2015) and one
was a conference abstract for which we could access the full paper (Reiss et al. 2015a). The
interventions evaluated included a call center (Reiss et al. 2015a), training courses (Fetters
et al. 2015; Reiss et al. 2015a; Tamang, Puri, Lama, and Shrestha 2015), printed materials
(Tamang, Puri, Lama, and Shrestha 2015), and one-to-one education visits (Reiss et al. 2015a).
All of the interventions aimed to improve the knowledge of pharmacy workers and were
graded as low quality, commonly lacking random allocation to the intervention, blinding of
participants, and adequate comparisons between groups or over time (see Table 3 for full
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scores). The study from Bangladesh was a cross-sectional post-intervention analytical study.
The studies conducted in Zambia and Nepal were pre- and post-intervention evaluations.
Only one of the studies included a comparison group of pharmacies from a non-intervention
area (Tamang, Puri, Lama, and Shrestha 2015). The cross-sectional study was the only one to
use probabilistic sampling and to adjust for potential confounding factors (Reiss et al. 2015a).
A wide range of outcomes were included in the studies (Table 6), but no studies included data
on cost-effectiveness.
Results of Interventions
Training interventions were evaluated in all three studies, and reported results were positive.
A one-day training course in Zambia was associated with self-reported increases in referrals,
provision of information about MA to clients, and sales of misoprostol when participants
were interviewed 12–24 months later (Fetters et al. 2015). As there was no control group,
however, the evidence that these increases are related to training, rather than reflecting gen-
eral improvements in awareness and knowledge, is weak, and self-reported outcomes may
reflect courtesy bias. A two-day training intervention was conducted in Nepal, augmented
by printed materials, referral vouchers, and interactive meetings between pharmacy workers
and abortion providers. The study also included refresher training after 10 months and an
end-line evaluation at one year. At baseline, knowledge of MA in both the intervention and
control groups was high, which the authors speculated was due to recent NGO training in
the area, but knowledge fell among the control group during the study, highlighting the need
for training to be periodic (Tamang, Puri, Lama, and Shrestha 2015).
The use of a call center to improve pharmacy worker knowledge was as-
sessed in Bangladesh. Knowledge was greater among pharmacy workers who had
contact with a call center (set up by an international NGO to provide information on
MA) after adjusting for potential confounding factors (Reiss et al. 2015a). The Bangladesh
study also assessed whether knowledge was higher among pharmacy workers who reported
receiving pharmaceutical company visits or training from an NGO; there was some evidence
that NGO training had a positive effect. However, since this study did not collect baseline
data, the associations cannot be assumed to be causal.
DISCUSSION
The studies in this systematic review suggest that provision of abortifacients by pharmacy
workers and drug sellers in LMICs is common, as is provision of medications to induce abor-
tion without a prescription (including effective and ineffective drugs). The highest quality ev-
idence of these findings relates toMexico, India, Bangladesh, and Nepal, but there were stud-
ies of reasonable methodological quality from sub-Saharan Africa (Nigeria, Zambia, Sene-
gal, Kenya), Latin America (Peru and Dominican Republic), and Asia (India, Bangladesh,
Vietnam, Nepal). However, in Latin America, there was a paucity of high-quality recent
studies (published in the last 5 years) from countries other than Mexico, and some studies
from the 1990s are of limited relevance today. Use of standardized indicators and repeated
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cross-sectional studies would improve comparability between regions and over time to as-
sess trends in MA availability in pharmacies and drug shops.
In general, the review found that the information provided by individuals working in
pharmacies and drug shops was poor, with many recommending ineffective drugs, few ad-
vising an effective regimen, and few giving information on potential complications and what
to do if they occur. Poor-quality products and information provision by pharmacies is not
a problem unique to MA. Incorrect advice and inappropriate supply of medicines in LMIC
pharmacies have been documented for health services ranging from childhood diarrhea to
tuberculosis (Smith 2009).However, stigma and legal restrictions related to abortionmay cre-
ate additional challenges for quality of pharmacy provision ofMA, not least because drugs are
often used off-label. In Africa the reported level of provision (proportion of pharmacy work-
ers/drug sellers who offered MA drugs/ mystery clients who were offered MA) was higher in
less restrictive settings (i.e. Zambia), but this was not the case in other regions such as Latin
America, where provision was relatively high despite legal restrictions. The highest levels of
knowledge of the MA regimen were also found in settings where abortion was less legally
restricted (India, Nepal).
We found only three studies that evaluated interventions to improve pharmacy worker
knowledge or practice of MA, despite the search including unpublished grey literature. All
three studies were in settings where abortion/menstrual regulation had few legal restrictions,
suggesting that legal issuesmay be hindering interventions and research on this topic in other
regions. The studies did not have rigorous evaluation designs, and two of them lacked a con-
trol group. The studies found that pharmacy worker training, with some form of follow up,
can improve knowledge. One study suggested that call centers, but not pharmaceutical one-
to-one education visits, may be effective in improving knowledge among pharmacy workers.
The evidence for training is supported by two other systematic reviews which found that
educational initiatives have positive impacts on pharmacy provision of general health ser-
vices (Smith 2009; Wafula and Goodman 2010). However, the studies did not assess whether
improved knowledge resulted in higher quality provision practice. Research suggests that in-
creased knowledge of MA regimens may not result in improved counseling (Powell-Jackson,
Acharya, Filippi, and Ronsmans 2015). Additionally, none of the studies in this review looked
at the costs or cost-effectiveness of the interventions; there are an estimated 210,000 reg-
istered and unregistered drug sellers in Bangladesh (Uzzal 2014), and 40,000 in Vietnam
(Minh, Huong, Byrkit, and Murray 2013), so scaling up training initiatives to the national
level may not be feasible in many LMICs. High mobility of pharmacies (either moving loca-
tion or closing down) (Hendrickson et al. 2015), high turnover of staff, and high numbers
of informal drug sellers are also challenges to the feasibility of scaling up training initiatives.
In this review, as in others (Smith 2009; Wafula and Goodman 2010), there was no evalua-
tion of more innovative approaches to improving pharmacy performance, such as incentive
structures, feedback, or regulatory mechanisms. Further evidence is needed on efficient ways
of strengthening the information pharmacy workers receive about MA, such as one-to-one
education meetings and telemedicine.
Most of the interventions in this review were targeted at changing pharmacy worker be-
havior. Evidence is also needed on the effectiveness of interventions to provide information
directly to womenwho purchaseMAdrugs from pharmacies/drug shops and self-administer
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the medications. The WHO task-sharing guidelines for abortion recommend against phar-
macy provision ofMA, because of a lack of comparative evidence (WorldHealthOrganization
2012), but recommend self-management for sub-tasks ofMA in circumstances where women
have access to appropriate information and emergency care. Directly providing women with
the information they need to self-manage amedical abortion, for example through telephone
hotlines, may improve the outcomes of women who purchase MA from drug shops and re-
duce the potential harm of unsafe abortion. However, women may continue to purchase in-
effective medicines sold as abortifacients from pharmacies and drug shops if effective MA
drugs are not available or if they cannot afford the most effective medications and are sold an
inferior product. Evaluations of strategies to reduce sales of unsafe, ineffective, and incorrect
medications are also needed.
This review has a number of limitations. First, in the search process we found several rele-
vant study abstracts but could not access full-text reports, so these are necessarily excluded, as
were some relevant studies that used only qualitative methods. We also found studies evalu-
ating innovative interventions such as telemedicine for reducing risk from unsafeMA, but we
could not include these studies as theywere not directed exclusively at pharmacy or drug shop
provision. The research field is small and we necessarily had to include studies that some of
us had authored ourselves. To avoid potential ethical bias, the quality scoring was conducted
only by non-authors of the paper being reviewed, and were checked by a second external re-
viewer. The heterogeneity of the study designs and outcomes posed challenges for selecting
an appropriate methodological appraisal tool, particularly for the intervention studies. The
tool we used to assess the intervention studies—CASP—was designed to evaluate random-
ized controlled trials. Although we adapted the question wording, our use of this tool meant
that the intervention studies (only one of which had a control group)were appraised relatively
harshly. Trends over time, between countries, and across regions could not be clearly assessed
given the variability of methods used, indicators measured, and locations where the studies
took place. Because most studies included in the review were cross-sectional, we could not
assess within-country temporal trends. We also were unable to assess the quality of products
offered or sold because none of the studies tested products, and we were unable to compare
product costs across studies given the lack of data. The issue of MA product quality has been
addressed only to a limited degree and warrants further attention (Hall 2016). The quality of
studies selected was mixed, and intervention studies were not methodologically strong, often
relying on small or convenience samples and using inadequate designs. This may reflect the
challenge of conducting interventions and evaluations on a legally restricted practice. Finally,
we included studies that reported on a number of different outcomes, making comparisons
difficult.
CONCLUSION
Availability ofMA in pharmacies and drug shops in LMICs is common, and evidence suggests
that women seek assistance from such outlets when faced with an unwanted pregnancy. Phar-
macies can expand access to medications for MA, but they do not always provide the right
products or effective regimens, and the quality of their knowledge and information provision
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is often poor. Despite increasing research, there is a lack of high-quality evidence in many
settings where abortion is more highly restricted. The use of pharmacies and drug shops as
a first port of call for health care, and the poor quality of health care provided by pharmacy
workers and drug sellers, are not limited to abortion. However, leveraging the benefits of
pharmacies and drug shops, such as their perceived accessibility, affordability, and confiden-
tiality, has great potential to reduce the harm caused by unsafe abortion. More innovative
interventions and rigorous evaluations that include cost-effectiveness are needed to build the
evidence base on what works to improve provision through pharmacy workers and drug sell-
ers and to increase women’s access to information. To reduce the consequences of unsafe
abortion, interventions cannot rely solely on pharmacy workers and drug sellers providing
higher quality information, but should seek to ensure that women have direct access to the
information they need to self-administer medical abortion.
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